Andrew Staron MD
Assistant Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7011andrew.staron@bmc.org
astaron@bu.edu
Sections
Hematology & Medical Oncology
Biography
Andrew Staron, MD is an Assistant Professor of Medicine in Hematology & Medical Oncology at the Chobanian and Avedisian School of Medicine. He was appointed to this position after completing his residency (2015–2018) and fellowship (2019–2022) at Boston Medical Center. In his third year of fellowship, Dr. Staron was selected for the role of chief fellow. Additionally, he completed a year-long clinical and research fellowship in amyloidosis (2018–2019) at the Boston University Amyloidosis Center, under the mentorship of the director, Dr. Sanchorawala.
As a practicing hematologist at Boston Medical Center, Dr. Staron has a deep commitment to serving patients and families who are affected by various hematologic diseases and who come from diverse backgrounds, drawing upon his own upbringing in an immigrant family. His main research interest is in AL amyloidosis—a rare plasma cell disorder that leads to the accumulation of abnormal immunoglobulin light chain proteins in organs. He has been the lead author on several publications in peer-reviewed journals and given presentations related to AL amyloidosis at national and international meetings. Dr. Staron helps to oversee the clinical database at the Boston University Amyloidosis Center and is directly involved in research projects utilizing this resource. He has conducted natural history studies that described important trends in disease outcomes and explored the role of minimal residual disease assessment in AL amyloidosis. Dr. Staron is also a member of the International Society of Amyloidosis and a peer-reviewer for several journals.
Education
Medicine, MD, New York Medical College
Biology, BS, Cornell University
Publications
Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Bawa PS, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. bioRxiv. 2024 Mar 16. PMID: 38558967.
Published on 10/24/2023Gustine JN, Staron A, Mendelson L, Joshi T, Gopal DM, Siddiqi OK, Ruberg FL, Sanchorawala V. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv. 2023 Oct 24; 7(20):6080-6091. PMID: 37581513.
Published on 6/1/2023Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684. PMID: 36546447.
Published on 5/8/2023Freydman J, Staron A, Hughes D, Sloan JM. Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome. J Oncol Pharm Pract. 2023 Sep; 29(6):1489-1493. PMID: 37157792.
Published on 1/31/2023Staron A, Mendelson LM, Joshi T, Ruberg FL, Sanchorawala V. Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre. Amyloid. 2023 Sep; 30(3):297-302. PMID: 36718932.
Published on 1/4/2023Verma K, Zhang T, Mueller D, Li J, Sanchorawala V, Staron A. Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report. Diagn Pathol. 2023 Jan 04; 18(1):1. PMID: 36597112.
Published on 7/5/2022Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199. PMID: 35731907.
Published on 7/4/2022Staron A, Zheng L, Doros G, Sanchorawala V. Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans. Blood Cancer J. 2022 07 04; 12(7):100. PMID: 35787622.
Published on 5/2/2022Staron A, Verma K, Sanchorawala V. Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis. Br J Haematol. 2022 Sep; 198(5):861-865. PMID: 35499208.
Published on 8/4/2021Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, Sanchorawala V. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021 08 04; 11(8):139. PMID: 34349108.